Last reviewed · How we verify

NCT03541265

Liposomal Bupivacaine in Total Knee Arthroplasty

Completed NA Last updated 30 May 2018
What this trial tests

NA trial testing Exparel in Knee Osteoarthritis in 70 participants. Completed in 1 March 2018.

Timeline
1 May 2016
Primary endpoint
1 June 2017
1 March 2018

Quick facts

Lead sponsorBronx-Lebanon Hospital Center Health Care System
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment70
Start date1 May 2016
Primary completion1 June 2017
Estimated completion1 March 2018

Drugs / interventions tested

Conditions studied

Sponsor

Bronx-Lebanon Hospital Center Health Care System

Who can join

25 and older, any sex, with Knee Osteoarthritis or Anesthesia, Local. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pain management after total knee arthroplasty is essential for optimized clinical outcomes and higher satisfaction. Exparel (Pacira Pharmaceuticals, Parsippany, New Jersey, USA) is a long-acting Bupivacaine extended release liposome compound that is injected peri-articularly or as regional block. The purpose of this study was to compare the analgesic efficacy of single administration of Exparel for local peri-articular infiltration versus adductor canal regional block.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Exparel

Trials testing the same drug.

Other recruiting trials for Knee Osteoarthritis

Currently open trials in the same condition.

Other Bronx-Lebanon Hospital Center Health Care System trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03541265.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing